Skip to main content
OpenTrials
Completed

NCT Number: NCT05887791

Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects

To investigate the effect of two different dosages collagen hydrolysate (CH) on postprandial blood glucose and insulin profile in prediabetic and normo-glycaemic subjects.This will be investigated in a cross-over randomized double-blind placebo controlled study design.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

BioTeSys GmbH

Esslingen am Neckar, 73728, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Main Inclusion Criteria:

  • Prediabetic subjects: Male and female subjects with prediabetic HbA1c values between 5.7% and 6.4% and/or fasting glucose ≥ 100 mg/dL and ≤ 125 mg/dL (in venous plasma) (twice confirmed at two independent days if HbA1c is < 5.7%) or Healthy normo-glycaemic subjects: fasting glucose <100 mg/dL and HbA1c is < 5.7%
  • Age: 18-70 years
  • Body mass index 19-35 kg/m2
  • Current Non-smoker
  • Signed informed consent form
  • No changes in food habits or physical activity 3 months prior to screening and during the study
  • If applicable, stable intake of chronic medication of at least 4 weeks

Main Exclusion Criteria:

  • Subjects with diagnosed Type 2 Diabetes mellitus with medical treatment
  • Presence of disease or drug(s) influencing digestion (incl. recent intake of antibiotics) and absorption of nutrients
  • Intake of medications known to affect glucose tolerance, e.g., diabetic medication, SGLT-2 inhibitors, GLP-1 receptor agonists, steroids, protease inhibitors or antipsychotics
  • Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the Investigator's opinion would impact patient safety
  • Severe liver or renal disease or laboratory evidence of hepatic dysfunction (i.e. alkaline phosphatase, ALT, AST >3 x ULN)
  • Known inflammatory or malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer, pancreatitis)
  • Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs
  • Intake of food supplements known to affect glucose tolerance, e.g., cinnamon capsules, conjugated linoleic acids
  • Drug-, alcohol- and medication abuses
  • Pregnant or breast-feeding women

Treatment and study plan

Collagen Hydrolysate

Dietary Supplement

Single dose

Placebo

Other

Single dose

Primary outcomes

  1. Glucose iAUC

    Time frame: 0-180 minutes postprandially

    Area under the curve (AUC) calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-180minutes)

Secondary outcomes

  1. Glucose iAUC

    Time frame: 0-240 minutes postprandially

    Area under the curve calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-240minutes)

  2. Glucose Cmax

    Time frame: 0-180 minutes postprandially

    Maximum blood glucose concentration (Cmax)

  3. Delta Cmax

    Time frame: 0-180 minutes postprandially

    Maximum increase of blood glucose concentration

  4. Tmax

    Time frame: 0-180 minutes postprandially

    Time to reach maximum blood glucose concentration (Tmax)

  5. T baseline

    Time frame: 0-240 minutes postprandially

    First time to reach baseline again after increase or decrease in blood glucose

  6. Matsuda-Index

    Time frame: 0-120 minutes postprandially

    Determination of Insulin sensitivity

  7. Glucose dip

    Time frame: 0-240 minutes postprandially

    maximum dip below baseline and time point of glucose dip

  8. Insulin iAUC

    Time frame: up to 0-240 minutes postprandially

    Area under the curve calculated as the incremental area under the insulin curve

  9. GLP-1

    Time frame: 0-120 minutes postprandially

    Incretin response (Glucagon-like Peptide-1)

  10. Satiety assessment

    Time frame: 0-240 minutes postprandially

    Visual analog scale (VAS) Scale (0: not at all 100: extremely)

Other outcomes

  1. Gastrointestinal hormones

    Time frame: 0-120 minutes postprandially

    Peptid YY (PYY), Ghrelin, Cholecystokinin (CCK), Leptin, Glucose-dependent Insulinotropic Polypeptide (GIP)

  2. Amino acids

    Time frame: 0-240 minutes postprandially

    Concentration-time curve of amino acids in plasma together with small molecular weight peptides

Sponsors and collaborators

Lead sponsor

Rousselot BVBA

Industry

Collaborators

  • BioTeSys GmbH

Registry information

Official study title

Clinical Study to Assess the Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects: Randomized, Double-blind, Placebo-controlled, Cross-over Study With Different Dosages

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Jun 5, 2023
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.